| 1 |
Ahmadi M, Emzhik M, Mosayebnia M. Nanoparticles labeled with gamma-emitting radioisotopes: an attractive approach for in vivo tracking using SPECT imaging. Drug Deliv Transl Res 2023. [PMID: 36811810 DOI: 10.1007/s13346-023-01291-1] [Reference Citation Analysis]
|
| 2 |
Hernández-Jiménez T, Cruz-Nova P, Ancira-Cortez A, Gibbens-Bandala B, Lara-Almazán N, Ocampo-García B, Santos-Cuevas C, Morales-Avila E, Ferro-Flores G. Toxicity Assessment of [(177)Lu]Lu-iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes. Nanomaterials (Basel) 2022;12. [PMID: 36500804 DOI: 10.3390/nano12234181] [Reference Citation Analysis]
|
| 3 |
Hernandez Vargas S, AghaAmiri S, Ghosh SC, Luciano MP, Borbon LC, Ear PH, Howe JR, Bailey-Lundberg JM, Simonek GD, Halperin DM, Tran Cao HS, Ikoma N, Schnermann MJ, Azhdarinia A. High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. Mol Pharm 2022;19:4241-53. [PMID: 36174110 DOI: 10.1021/acs.molpharmaceut.2c00583] [Reference Citation Analysis]
|
| 4 |
Ma J, Yu D, Zhao D, Huang T, Dong M, Wang T, Yin H. Poly-Lactide-Co-Glycolide-Polyethylene Glycol-Ginsenoside Rg3-Ag Exerts a Radio-Sensitization Effect in Non-Small Cell Lung Cancer. j biomed nanotechnol 2022;18:2001-2009. [DOI: 10.1166/jbn.2022.3434] [Reference Citation Analysis]
|
| 5 |
Chen C, Chan Y, Lin S, Chiang HK, Lee Y, Chuang H. Theranostic Radiolabeled Nanomaterials for Molecular Imaging and potential Immunomodulation Effects. J Med Biol Eng . [DOI: 10.1007/s40846-022-00715-6] [Reference Citation Analysis]
|
| 6 |
Desai P, Rimal R, Sahnoun SEM, Mottaghy FM, Möller M, Morgenroth A, Singh S. Radiolabeled Nanocarriers as Theranostics—Advancement from Peptides to Nanocarriers. Small. [DOI: 10.1002/smll.202200673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol 2021;102-103:1-11. [PMID: 34242948 DOI: 10.1016/j.nucmedbio.2021.06.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 8 |
Pellico J, Gawne PJ, T M de Rosales R. Radiolabelling of nanomaterials for medical imaging and therapy. Chem Soc Rev 2021;50:3355-423. [PMID: 33491714 DOI: 10.1039/d0cs00384k] [Cited by in Crossref: 50] [Cited by in F6Publishing: 60] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 9 |
Chakraborty J, Banerjee I, Vaishya R, Ghosh S. Bioengineered in Vitro Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation.ACS Biomater Sci Eng. 2020;6:6540. [PMID: 33320635 DOI: 10.1021/acsbiomaterials.0c01226] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 10 |
Ambrogio MW, Toro-gonzález M, Keever TJ, Mcknight TE, Davern SM. Poly(lactic- co -glycolic acid) Nanoparticles as Delivery Systems for the Improved Administration of Radiotherapeutic Anticancer Agents. ACS Appl Nano Mater 2020;3:10565-70. [DOI: 10.1021/acsanm.0c02350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 11 |
Mohtavinejad N, Shafiee Ardestani M, Khalaj A, Pormohammad A, Najafi R, Bitarafan-Rajabi A, Hajiramezanali M, Amanlou M. Application of radiolabeled peptides in tumor imaging and therapy. Life Sci 2020;258:118206. [PMID: 32758623 DOI: 10.1016/j.lfs.2020.118206] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 12 |
Maqsood MH, Tameez Ud Din A, Khan AH. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review. Cureus. 2019;11:e3986. [PMID: 30972265 DOI: 10.7759/cureus.3986] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 13 |
Geng X, Zhang M, Lai X, Tan L, Liu J, Yu M, Deng X, Hu J, Li A. Small-Sized Cationic miRi-PCNPs Selectively Target the Kidneys for High-Efficiency Antifibrosis Treatment. Adv Healthc Mater 2018;7:e1800558. [PMID: 30277665 DOI: 10.1002/adhm.201800558] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 14 |
Arora G, Bandopadhyaya G. Paradigm shift in theranostics of neuroendocrine tumors: conceptual horizons of nanotechnology in nuclear medicine. Ann Nucl Med 2018;32:151-64. [PMID: 29374820 DOI: 10.1007/s12149-018-1235-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 15 |
Amoroso AJ, Fallis IA, Pope SJ. Chelating agents for radiolanthanides: Applications to imaging and therapy. Coordination Chemistry Reviews 2017;340:198-219. [DOI: 10.1016/j.ccr.2017.01.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 16 |
Tian L, Chen Q, Yi X, Chen J, Liang C, Chao Y, Yang K, Liu Z. Albumin-Templated Manganese Dioxide Nanoparticles for Enhanced Radioisotope Therapy. Small 2017;13. [PMID: 28544324 DOI: 10.1002/smll.201700640] [Cited by in Crossref: 60] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 17 |
Navarro SM, Swetledge S, Morgan T, Astete CE, Stout R, Coulon D, Sabliov CM. Biodistribution of orally administered poly(lactic-co-glycolic) acid nanoparticles for 7 days followed by 21 day recovery in F344 rats. NanoImpact 2017;5:1-5. [DOI: 10.1016/j.impact.2016.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 18 |
Arora G, Dubey P, Shukla J, Ghosh S, Bandopadhyaya G. Evaluation of cytotoxic and tumor targeting capability of 177Lu-DOTATATE-nanoparticles: a trailblazing strategy in peptide receptor radionuclide therapy. Ann Nucl Med 2016;30:334-45. [DOI: 10.1007/s12149-016-1067-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 19 |
Lee SH, Lee JB, Bae MS, Balikov DA, Hwang A, Boire TC, Kwon IK, Sung HJ, Yang JW. Current progress in nanotechnology applications for diagnosis and treatment of kidney diseases. Adv Healthc Mater 2015;4:2037-45. [PMID: 26121684 DOI: 10.1002/adhm.201500177] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 20 |
Lee DS, Im H, Lee Y. Radionanomedicine: Widened perspectives of molecular theragnosis. Nanomedicine: Nanotechnology, Biology and Medicine 2015;11:795-810. [DOI: 10.1016/j.nano.2014.12.010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 21 |
Phillips WT, Bao A, Brenner AJ, Goins BA. Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles. Adv Drug Deliv Rev 2014;76:39-59. [PMID: 25016083 DOI: 10.1016/j.addr.2014.07.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 22 |
Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013;40:56-68. [PMID: 23391113 DOI: 10.1053/j.seminoncol.2012.11.006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 23 |
Raghunathan R, Mahesula S, Kancharla K, Janardhanan P, Jadhav YL, Nadeau R, Villa GP, Cook RL, Witt CM, Gelfond JA, Forsthuber TG, Haskins WE. Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL. Part Part Syst Charact 2013;30:355-64. [PMID: 23976822 DOI: 10.1002/ppsc.201200125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
